Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors

Nivolumab is a fully human monoclonal antibody that inhibits programmed death‐1 activation. The clinical pharmacology profile of nivolumab was analyzed by a population pharmacokinetics model that assessed covariate effects on nivolumab concentrations in 1,895 patients who received 0.3–10.0 mg/kg niv...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajaj, G, Wang, X, Agrawal, S, Gupta, M, Roy, A, Feng, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270302/
https://www.ncbi.nlm.nih.gov/pubmed/28019091
http://dx.doi.org/10.1002/psp4.12143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270302/
https://www.ncbi.nlm.nih.gov/pubmed/28019091
http://dx.doi.org/10.1002/psp4.12143

Ejemplares similares